Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification
| Autor: | Morie A. Gertz, Shaji Kumar, Elizabeth J. Nista, Angela Dispenzieri, Martha Q. Lacy, Yubin Kang, Kathy Hogan Edwards, Luciano J. Costa, Cindy Kramer, Robert K. Stuart, Francis K. Buadi |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Filgrastim medicine.medical_treatment CD34 Antigens CD34 Cohort Studies Internal medicine medicine Humans Platelet Multiple myeloma Aged Retrospective Studies Lenalidomide Transplantation Mobilization business.industry Growth factor Plerixafor Hematology Middle Aged medicine.disease Hematopoietic Stem Cell Mobilization Surgery Stem cell mobilization Female Multiple Myeloma business medicine.drug |
| Zdroj: | Biology of Blood and Marrow Transplantation. 20:222-228 |
| ISSN: | 1083-8791 |
| DOI: | 10.1016/j.bbmt.2013.11.003 |
| Popis: | It is unknown whether clinical characteristics can successfully predict which multiple myeloma (MM) patients would be poor mobilizers with growth factor (GF) alone so they can be assigned to mobilization with chemotherapy + GF or GF + plerixafor. MM patients (N = 477) who underwent autologous mobilization with GF were retrospectively reviewed and assigned into training and validation cohorts. In multiple regression analysis, age, platelet count at time of mobilization, type of GF utilized, and extent of exposure to lenalidomide independently correlated with peripheral blood (PB)-CD34+ and were integrated in a predicting score (PS) for poor mobilizers, defined as PB-CD34+ |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect